EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of Primary Hyperoxaluria Type III by Gas Chromatography/Mass Spectrometry-Based Urine Metabolomics

Tomiko Kuhara iD, Morimasa Ohse, Tatsuya Fukasawa, Koichi Maruyama, James Pitt iD

Metabolites · 19.04.2026 · 16 (4) · 278

DOI: 10.3390/metabo16040278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolites, online erschienen am 19.04.2026. Verfasst von Tomiko Kuhara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Japan Clinical Metabolomics Institute, Kahoku 929-1174, Japan. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Primary hyperoxaluria type III (PH3) causes kidney stones in children and adults. Gas chromatography/mass spectrometry (GC/MS)-based metabolomics has been applied to study patients with primary hyperoxaluria types I and II, 2,8-dihydroxyadenine lithiasis, and xanthinuria types I to III. This study was performed to verify the usefulness of this technique for the diagnosis of PH3. Specifically, we evaluated an 8-month-old infant with recurrent kidney stones.

Methods

GC/MS-based metabolomics was performed on spot urine samples using initial urease pretreatment without fractionation.

Results

Metabolomics revealed increased levels of 2,4-dihydroxyglutarate and 4-hydroxyglutamate. No simultaneous elevations of these two critical biomarkers were observed in other patients, except for one case of PH3 confirmed by the identification of HOGA1 mutations. A moderate increase in 4-hydroxyglutamate has been observed only in cases of primary hyperammonemia, in which analytes such as orotate, uridine, glutamine, or proline, but not 2,4-dihydroxyglutarate, are biomarkers, thus distinguishing PH3 from primary hyperammonemia.

Conclusions

GC/MS-based urine metabolomics enables the rapid screening and chemical diagnosis of PH3 and other congenital anomalies that cause urolithiasis. This technique can also be used to monitor disease progression, as patients with PH3 benefit from long-term follow-up, particularly when transitioning from childhood to adulthood. The timely identification of patients with hereditary urolithiasis is crucial. To address this, a discussion was had about the current diagnostic criteria.

Schlagwörter

Stichwörter der Autor:innen

HOGA1diagnosisdiagnostic criteriahereditary urolithiasiskidney stone diseasemetabolomicsprimary hyperoxaluria type 3

Autor:innen und Institutionen

  • Japan Clinical Metabolomics Institute, Kahoku 929-1174, Japan.
  • Anjo Kosei Hospital, Anjo 446-8602, Japan.
  • Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne 3052, Australia.

ORCID-Profile: Tomiko Kuhara, James Pitt

Zitieren

APA

Kuhara, T., Ohse, M., Fukasawa, T., Maruyama, K., & Pitt, J. (2026). Identification of Primary Hyperoxaluria Type III by Gas Chromatography/Mass Spectrometry-Based Urine Metabolomics. Metabolites, 16(4), 278. https://doi.org/10.3390/metabo16040278

Vancouver

Kuhara T, Ohse M, Fukasawa T, Maruyama K, Pitt J. Identification of Primary Hyperoxaluria Type III by Gas Chromatography/Mass Spectrometry-Based Urine Metabolomics. Metabolites. 2026;16(4):278. doi:10.3390/metabo16040278

BibTeX
@article{Kuhara2026,
  author = {Kuhara, Tomiko and Ohse, Morimasa and Fukasawa, Tatsuya and Maruyama, Koichi and Pitt, James},
  title = {Identification of Primary Hyperoxaluria Type III by Gas Chromatography/Mass Spectrometry-Based Urine Metabolomics},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {278},
  doi = {10.3390/metabo16040278}
}
Kostenlos starten →